SITC Session at 2023 ASH Summit on Immunotherapies for Hematologic Diseases

When:  Mar 3, 2023 from 14:55 to 16:10 (ET)

The American Society of Hematology (ASH) provides the most current practice tools, clinical support, and educational products in hematology that you need for every stage of your career. Our family of sites, developed by subject-matter experts, are designed to help physicians improve their medical knowledge, engage in quality activities, meet and learn from thousands of hematologists worldwide and continue to help conquer blood diseases worldwide.

Session #8: Late Breaking Special Session (ASH-SITC JOINT Session)


John Tisdale, MD - NIH Molecular & Clinical Hematology

Nina Shah, MD - University of California San Diego


The Immune Predictors of Response to CAR T and Bispecific T Cell Therapy 
Paola Neri, MD, PhD - University of Calgary

Novel Technologies to Improve and Safely Deliver Gene Therapies 
Jennifer E. Adair, PhD - Fred Hutchinson Cancer Center


Dr. Paola Neri will discuss the Immune predictors of response to chimeric antigen receptor (CAR) T and bispecific T cell therapy in multiple myeloma (MM). She will start by describing the mechanisms of tumor escape that allow MM progression and development of immune dysfunction. Next, she will review the T-Cell based strategies developed to overcome immune escape with a focus on CAR-T and bispecific T cell therapy. Lastly, Dr. Neri will discuss the causes of resistance to these therapies and how a comprehensive genomic analysis of the tumor together with the study of the immune cell repertoire can help to identify patients with the highest likelihood of respond to these therapies and lead to the development of prevention strategies. 


Omni Shoreham Hotel
2500 Calvert Street NW
Washington, DC 20008